Jun-liang Fu

100 Western 4th Ring Road
Beijing, 100039, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

A preS2 aa1-26-specific humoural response marks functional cure in chronic HBV infection.

A preS2 aa1-26-specific humoural response marks functional cure in chronic HBV infection.

Journal: EBioMedicine

Published: March 04, 2026

Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights.

Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights.

Journal: Signal transduction and targeted therapy

Published: January 19, 2025

Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial.

Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial.

Journal: Stem cell research & therapy

Published: June 13, 2024

Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial.

Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial.

Journal: EBioMedicine

Published: February 04, 2023

Boosting viral-specific immunotherapy for chronic hepatitis B treatment.

Boosting viral-specific immunotherapy for chronic hepatitis B treatment.

Journal: Cellular & molecular immunology

Published: September 26, 2021

Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial.

Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial.

Journal: EBioMedicine

Published: August 03, 2021

Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.

Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.

Journal: Hepatology international

Published: April 30, 2021

Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial.

Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial.

Journal: Hepatology international

Published: January 08, 2021

Systematic Discovery and Pathway Analyses of Metabolic Disturbance in COVID-19.

Systematic Discovery and Pathway Analyses of Metabolic Disturbance in COVID-19.

Journal: Infectious diseases & immunity

Published: January 04, 2021

Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.

Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.

Journal: Signal transduction and targeted therapy

Published: November 21, 2020

Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis.

Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis.

Journal: Cell metabolism

Published: May 08, 2020

Single-cell landscape of immunological responses in patients with COVID-19.

Single-cell landscape of immunological responses in patients with COVID-19.

Journal: Nature immunology

Published: May 07, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026